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BACKGROUND Bioresorbable everolimus-eluting scaffolds (BVS) and
metallic drug-eluting stents with bioabsorbable polymers (MBP-DES)
have shown positive clinical results in studies. Direct comparative
evaluation between both for the process of endothelialization is
lacking and could be relevant to deﬁne their safety proﬁle and sub-
sequently estimate the appropriate duration of dual antiplatelet-
therapy. In this study we sought to evaluate endothelialization of BVS
and MBP-DES, implanted both in same patient, with OCT performed at
6 and 12 months.
METHODS Multicenter (16 centers) prospective study. Patients were
recruited when requiring stent implantation (without overlapping) in
at least two separate lesions of similar morphologic characteristics.
Each lesion was randomized to be treated with a BVS or a MBP-DES
(Synergy TM, Orsiro TM or Biomatrix TM). After the procedure pa-
tients were scheduled alternatively for 6 or 12 months evaluation with
optical coherence tomography. Co-primary endpoints are % of un-
covered struts at 6 and 12 months.
RESULTS Up to date 100 patients have been included all treated in at
least one lesion with a BVS and in at least other lesion with a MBP-DES
(50% Synergy TM, 25% Orsiro TM and 25% Biomatrix TM). Among
these, 20 patients have been so far examined with OCT at 6 months.
The proportion of uncovered struts was 2.8  2.4 % with MBP-DES and
3.2  3.8 % with BVS (p¼0.4) and the proportion of malapposed struts
was 2.2  2.8 % and 2  3.7% respectively (p¼0.7). Maximal malap-
position area was 1  1.3 mm2 with MBP-DES and 1.8  2.4 mm2 with
BVS (p¼0.1). Evaginations or protusion of covered struts were more
common with BVS.
CONCLUSIONS Pending of ﬁnal follow up and analysis of the whole
cohort, at 6 months the proportion of uncovered struts is very low
and comparable between bioresorbable everolimus-eluting scaffolds
and metallic drug-eluting stents with bioabsorbable polymers. Dif-
ferences in evagination and malapposition magnitude could be
observed.
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BACKGROUND Even though the limited randomized data suggest
similar angiographic and intermediate-term clinical outcomes in pa-
tients treated with bioresorbable scaffolds (BRS) and those treated
with new generation everolimus eluting stents (EES), real world
studies have revealed some worrying signals of increased rates of
stent thrombosis (ST) in patients treated with BRS. Several potential
ST mechanisms have been proposed, one of which involves over-
lapping segments. This propensity matched study sought to evaluate
procedural and clinical outcomes amongst stable angina patients
treated with percutaneous coronary intervention (PCI) with over-
lapping BRS or new generation EES.
METHODS A total of 109 consecutive stable angina patients treated
with overlapping BRS (May 2012-July 2014) and 149 patients treated
with overlapping new generation EES (January 2011 and July 2014) in
2 Italian centers were included. Exclusion criteria included bifurcation
lesions treated with a 2-stents/scaffolds strategy and patients with
end stage renal failure. After propensity matching, a total of 70 stable
angina patients treated with overlapping BRS and 70 patients treated
with overlapping new generation EES were included. The primary
outcomes were angiographic and procedural success. Secondary
endpoints included 1-year rate of major adverse cardiovascular events
(MACE: deﬁned as the composite of all-cause mortality, non-proce-
dural myocardial infarction (MI) and target-vessel revascularization).
RESULTS Post procedural acute gain was signiﬁcantly lower in pa-
tients treated with BRS (1.820.66mm versus 2.030.68mm,
p¼0.033). Angiographic success (BRS vs. EES: 94.3% vs. 95.5%,
p¼0.742), rates of periprocedural MI (BRS vs. EES: 7.1% vs. 5.7%,
p¼0.730) and procedural success (BRS vs. EES: 88.6% vs. 89.9%,
p¼0.854) were similar between the two groups. At 1-year follow up,
the estimated MACE rate was not signiﬁcantly different between the
two groups (BRS vs. EES: 14.5% vs. 15.9%; Plog-rank¼0.427). Similarly,
no signiﬁcant differences were seen in 1-year rates of TVR (BRS vs.
EES: 11.7% vs. 8.1%, Plog-rank¼0.8), TLR (BRS vs. EES: 7.5% vs. 6.5%,
Plog-rank¼0.917) or follow-up MI (BRS vs. EES: 0% vs. 0%,
Plog-rank¼0.098). No cases of deﬁnite stent thrombosis were observed
in the two groups.
CONCLUSIONS This small propensity matched study demonstrated
that treating long lesions with overlapping scaffolds is feasible and
safe with acceptable procedural outcomes. Even though there was a
signiﬁcantly lower acute gain in the BRS group compared to EES, this
did not translate into worse clinical outcomes. Future, large ran-
domized trials are needed to assess the clinical performance of BRS
compared to new generation EES in patients implanted with over-
lapping scaffolds.
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BACKGROUND The bioresorbable vascular scaffold (BVS) may facili-
tate restoration of normal coronary physiology after resorption of the
scaffold. Conversely, early after BVS implantation the mean luminal
area is decreased in comparison with conventional metal stents.
Therefore, a randomized clinical trial of BVS vs. metal drug eluting
stent (DES) was initiated, utilizing positron emission tomography
(PET) perfusion imaging to assess the impact of these phenomena on
(hyperemic) myocardial blood ﬂow (MBF) and CFR over a three year
period (VANISH-trial). These are the one-month results of the ongoing
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implantation.
METHODS Sixty patients (45 men (75%), 55  7 years) with a docu-
mented single vessel type A or B1 lesion, either stable or unstable
angina without biochemical signs of myocardial infarction, were
included in this single blind randomized clinical trial. Patients were
randomized to implantation of a DES or BVS (Xience Prime or
ABSORB, respectively) in a one-to-one fashion. Approximately 1
month after percutaneous coronary intervention patients underwent
H215O PET to assess (hyperemic) MBF, cold pressor test MBF, and
CFR.
RESULTS Lesions were predominantly located in the LAD (n¼36,
60%) and less frequently in the RCA (n¼14, 23%) or Cx (n¼10, 17%).
One patient refused PET perfusion at 1 month follow-up (DES arm).
MBF of the treated myocardial territory during rest, CPT, and hyper-
emia of DES was comparable with the BVS arm (0.96  0.24 vs. 1.02 
0.28 mLmin-1g-1, p¼0.38, 1.08  0.23 vs. 1.20  0.38 mLmin-1g-1,
p¼0.16, and 3.33  0.77 vs. 3.04  0.80 mLmin-1g-1, p¼0.16,
respectively). CFR of the treated territory was signiﬁcantly lower in
the BVS arm compared to DES (3.09  0.94 vs. 3.57  0.85, p<0.05). No
signiﬁcant differences in (hyperemic) MBF, CPT, and CFR were
documented in remote areas between treatment arms. Also, a trend
toward an attenuated remote CFR was observed in the BVS treatment
arm (3.03  0.86 vs. 3.48  0.96 mLmin-1g-1, p¼0.06).
CONCLUSIONS CFR is attenuated one month after implantation of a
BVS compared with a DES, although, quantitative hyperemic MBF was
not different between both treatment arms.
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BACKGROUND The safety and performance of the current Absorb
Bioresorbable Vascular Scaffold (Absorb BVS) (Abbott Vascular, Santa
Clara, CA) has been previously established in 101 patients enrolled in
the Cohort B of the First-in-Man ABSORB trial. At 48 months, MACE
rate in Cohort B was 10.1%, with no scaffold thrombosis (ST) reported.
ABSORB EXTEND was initiated as a global, continued access, inter-
national (outside of the US) study to expand the clinical experience
with the Absorb BVS to different geographies. Of note, investigators
were allowed to treat patients with longer coronary lesions and
smaller vessels than those in the Cohort B trial, using either longer
scaffold lengths or planned overlap with the 2.5-mm and 3.0-mm
Absorb BVS.
METHODS ABSORB EXTEND is a prospective, single-arm, open-label
clinical study that enrolled 812 subjects at 56 sites. Included were
patients with lesions  28 mm in length and reference vessel diameter
of 2.0 mm - 3.3 mm (as assessed by on-line QCA or IVUS). Treatment of
a maximum of two de novo native coronary artery lesions, each in a
different epicardial vessel, was permitted.
RESULTS Interim 24-month data in the ﬁrst 450 ABSORB EXTEND
study patients has been previously presented. Among patients
included, 33% had unstable angina, 29% prior MI and 27% diabetes
mellitus. Mean RVD and mean lesion length were 2.610.35 mm and
11.614.89 mm, respectively. In these 450 patients, hierarchical
MACE, TVF and def/prob ST rates at 2 years were 6.7%, 7.4% and 1.1%,
respectively. Long-term (36-month) follow-up data will be presented
for the ﬁrst 500 patients enrolled with the aim of providing substan-
tial data on long-term safety and performance of the Absorb BVS in a
larger population of patients, including those with planned over-
lapping and dual vessel treatment.
CONCLUSIONS Long-term outcomes in approximately 500 patients at
36 months (the largest patient cohort reported at this time point to
date) from ABSORB EXTEND will provide further insight into the
safety and performance of the Absorb BVS.
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BACKGROUND The aim of this single center observational study was
to investigate the feasibility of bioresorbable vascular scaffold (BVS)
in treatment in-stent restenosis lesions. In stent restenosis is still a
relatively common problem in daily practice. Existing solutions were
not fully effective so far. The use of drug-eluting stents (DES) is
related with increased thrombosis risk, also drug-eluting balloon has
disadvantage because the eluted-drug stays in the arterial wall only
for few weeks, which is not sufﬁcient to eliminate the risk of reste-
nosis. Bioresorbable scaffolds could be possible solution of this issue.
The BVS has a number of proposed advantages over current metallic
stent technology which could be helpful in providing short-term
vessel scaffolding and capability of prolonged drug delivery.
METHODS Between October 2013 and January 2015, 53 Patients (61
lesions) were enrolled in single arm prospective open label study in
which in stent restenosis lesions was suitable for BVS implantation.
Primary endpoints were procedural success of deployment of the BVS
at the target lesion and absence of in-hospital major adverse events
(death, Q-wave myocardial infarction, stroke or any repeat target
lesion revascularization). The mean patient age was 6412 years and
78% patients were male, 93% suffered from hypertension and 31%
from diabetes. PCI procedures were performed in 87% patients pre-
senting with stable CAD and 13% with acute coronary syndrome. Ac-
cording to the angiographic ISR pattern 45% lesions were focal and
55% were diffuse, the majority of the lesions was post DES ISR (79%).
Procedural OCT evaluation was performed in all lesions (100%) before
and post-BVS implantation. Estimate the size of the BVS was made on
the basis of the IVUS examination just after ﬁrst balloon predilatation.
Lesion pre-dilatation was mandatory and post dilatation was needed
in 92% of cases. After 6 month of BVS implantation clinical evaluation
was made, the next 6 month patients had performed control angiog-
raphy with OCT.
RESULTS Procedural success was obtained in all cases. No in-hospital
clinical events and intra-procedural or acute BVS-in-stent thrombosis
were reported. Mean BVS implanted length was 30,5 mm. A number of
1.6 stents were implanted per lesion. At a median of 6 months follow
up 2 clinically-driven TLR ( 3.8% per patient) were reported due to
recurrent ISR at the BVS-in-stent implantation site. No cardiac death,
Q-wave MI occurred at follow-up. Re-evaluation by angiography with
OCT will be obtained in next 12 months follow-up after procedure.
CONCLUSIONS The results of our study suggest that BVS is safe and
technically feasible for the treatment of ISR in patients presenting
with both stable CAD and ACS with reasonable midterm outcomes.
Moreover, follow-up revealed a very low rate of adverse events in
patients treated by BVS implantation in the context of treatment of in-
stent restenosis.
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BACKGROUND Bioresorbable everolimus-eluting scaffolds (BVS) and
the Pt-Cr everolimus-eluting stent with abluminal bioabsorbable
polymer (Synergy) have shown positive clinical results in trials.
However, there are important differences in the respective platforms
which could impact on clinical performance during implantation.
